- Home
- PKE vs ALT Comparison
PKE vs ALT Comparison
Compare PKE & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- ALT
- Stock Information
- Founded
- PKE 1954
- ALT 1997
- Country
- PKE United States
- ALT United States
- Employees
- PKE N/A
- ALT N/A
- Industry
- PKE Military/Government/Technical
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- PKE Industrials
- ALT Health Care
- Exchange
- PKE Nasdaq
- ALT Nasdaq
- Market Cap
- PKE 352.8M
- ALT 292.0M
- IPO Year
- PKE N/A
- ALT N/A
- Fundamental
- Price
- PKE $18.66
- ALT $3.83
- Analyst Decision
- PKE
- ALT Strong Buy
- Analyst Count
- PKE 0
- ALT 6
- Target Price
- PKE N/A
- ALT $17.40
- AVG Volume (30 Days)
- PKE 115.8K
- ALT 3.0M
- Earning Date
- PKE 10-14-2025
- ALT 08-12-2025
- Dividend Yield
- PKE 2.67%
- ALT N/A
- EPS Growth
- PKE 4.18
- ALT N/A
- EPS
- PKE 0.34
- ALT N/A
- Revenue
- PKE $63,456,000.00
- ALT $20,000.00
- Revenue This Year
- PKE N/A
- ALT N/A
- Revenue Next Year
- PKE N/A
- ALT $761,880.20
- P/E Ratio
- PKE $55.09
- ALT N/A
- Revenue Growth
- PKE 16.60
- ALT N/A
- 52 Week Low
- PKE $11.97
- ALT $2.90
- 52 Week High
- PKE $20.73
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- PKE 62.12
- ALT 51.79
- Support Level
- PKE $18.81
- ALT $3.35
- Resistance Level
- PKE $19.54
- ALT $3.66
- Average True Range (ATR)
- PKE 0.59
- ALT 0.19
- MACD
- PKE 0.02
- ALT 0.07
- Stochastic Oscillator
- PKE 77.04
- ALT 86.18
About PKE Park Aerospace Corp.
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.